News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication -- MALVERN, Pa., Jan.
View HTML
Toggle Summary Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
- Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck Cancer with Topline Data Expected in 1H 2021 -  MALVERN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc.
View HTML
Toggle Summary Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology
- GC4419 90 mg produced clinically meaningful reduction of severe oral mucositis duration, incidence and severity in Phase 2b clinical trial - MALVERN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing
View HTML
Toggle Summary Galera Therapeutics Announces Pricing of Initial Public Offering
MALVERN, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced
View HTML
Toggle Summary Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer
MALVERN, Penn. — October 10, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced Christopher Degnan has been
View HTML
Toggle Summary Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC4419
Data reinforce potential of GC4419 to become a promising treatment for reducing the incidence of severe oral mucositis in patients with head and neck cancer MALVERN, Penn. — October 8, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and
View HTML
Toggle Summary Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual Conference
Data to be published in the Journal of the National Comprehensive Cancer Network MALVERN, Penn. — March 21, 2019  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer
View HTML
Toggle Summary Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting
MALVERN, Penn. — October 23, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem
View HTML
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)
Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Penn. — October 15, 2018 —  Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development
View HTML
Toggle Summary Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 MALVERN, Penn. — September 19, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting
View HTML